Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy
Diabetic retinopathy (DR) is a microvascular disease caused by poorly controlled blood glucose, and it is a leading cause of vision loss in people with diabetes. In this review we discuss the current management of DR with particular focus on the use of intraocular anti-vascular endothelial growth fa...
Main Authors: | Tyler A. Bahr, Sophie J. Bakri |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/13/5/1098 |
Similar Items
-
Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy
by: Tsubota K, et al.
Published: (2019-06-01) -
Retinopathy of Prematurity: Treatment-Needed Patients, Treatment Complications, and Recurrence Rate
by: Mohammad-Reza Ansari_Astaneh, et al.
Published: (2023-08-01) -
The Association of Intravitreal Anti-VEGF Injections With Kidney Function in Diabetic Retinopathy
by: Casey C. Bunge, MD, et al.
Published: (2023-12-01) -
Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients
by: Yue Xu, et al.
Published: (2022-10-01) -
Managing proliferative diabetic retinopathy in a patient with vitreous hemorrhage: a case report
by: O. B. Koshchynets, et al.
Published: (2022-06-01)